How do I get a peptide vial tested by a lab like Janoshik?
What testing labs publish about sending in a vial yourself: listed price, method, minimum sample, turnaround, add-ons and what each number proves.
Research use only. This page provides scientific background and community-report context. Every compound sold here is supplied strictly for in-vitro research, not for human or veterinary use. Nothing on this page is a protocol, a recommendation or medical advice.
TL;DR: submission requirements and the limits of a report
The question people actually type: how do i get my peptide vial tested by a lab like janoshik
What the published data say: Janoshik lists an order followed by shipping instructions, an unopened vial requirement and an HPLC report covering identity, amount and peptide purity. Its archived price is USD 360.00 [Janoshik, snapshot 15 July 2026; published figures, subject to change].
What the documented searches did not identify: no published study reports laboratory analysis of consumer-purchased retatrutide vials in the documented PubMed and ClinicalTrials.gov searches dated 12 September 2026. The human case report did not analyze the vial [PMID 42669023].
What research communities report: in the Reddit corpus we track, 532 question posts in 12 months, 17 in the 4 to 12 Sept 2026 window matched this pattern. These are reports, not evidence of frequency or product quality [internal corpus audit].
What does the lab list for a GLP-1 vial test?
Janoshik's archived catalogue lists a blind test covering semaglutide, tirzepatide and retatrutide for USD 360.00 per sample [Janoshik, snapshot 15 July 2026]. All catalogue prices and service details below are published figures, subject to change, from that snapshot. They are not live-confirmed prices.
The listed method is HPLC. The service describes identification, amount and peptide purity; the lyophilizate result format is mg per vial and peptide purity. The submitter need not identify which of the named compounds is suspected. The catalogue also states that peptide purity may not be measurable when peptides are mixed together [Janoshik, snapshot 15 July 2026].
PeptidesDirect does not sell tirzepatide. PeptidesDirect does not sell semaglutide. Naming this analysis service describes its published scope and is not a vendor recommendation.
How much sample does submission require, and how long does testing take?
The catalogue requires 1 whole unopened vial for lyophilizate, compared with 30 mg in a sealed glass vial for raw API powder [Janoshik, snapshot 15 July 2026]. These are analytical sample requirements.
According to the catalogue, shipping instructions follow the order, and a report cannot be issued without a submitted sample. Group orders and payments are handled outside the e-shop. The published average turnaround is 7 business days; an average is not a promised completion date [Janoshik, snapshot 15 July 2026].
The listed detection cutoff is less than 1/20th of the usual per-vial amount. That is the catalogue's detection-limit description, not a quantity that a vial ought to contain [Janoshik, snapshot 15 July 2026].
Which add-ons does the catalogue list?
The catalogue lists separate analyses for batch variation, net peptide content and contamination, each with its own scope [Janoshik, snapshot 15 July 2026; published figures, subject to change].
- Batch variation: +USD 75.00, with all pieces from the same batch of the same product.
- Net peptide content: +USD 145.00 for CHNS elemental analysis, using nitrogen and sulfur measurements.
- Sterility: +USD 290.00 for TAMC and TYMC testing for bacteria and molds, requiring additional unopened pieces, with an average turnaround of 14 days.
- Endotoxin: +USD 180.00, offered only for finished products. The catalogue describes accuracy up to 10 EU/vial; results above 10 EU/vial are estimates.
- Heavy metals and identification screening: +USD 105.00 for As, Cd, Pb and Hg; +USD 205.00 for LCMS screening, which provides identification only. The catalogue sets the expedited-testing surcharge equal to the price of the tests being expedited.
These prices are add-ons, not the base test price. The sterility turnaround is separate from the base service average [Janoshik, snapshot 15 July 2026].
What does each result actually establish?
Identity, chromatographic purity and peptide quantity answer different analytical questions. Moore's pharmacopoeial overview distinguishes identity methods from HPLC measurements of purity and quantity [Moore 2023, PMC10338602, Table II].
Purity is a peak-area ratio; content in mg needs a reference standard. Neither substitutes for a separate microbial or endotoxin measurement. The catalogue's mixture caveat and detection cutoff also limit what its report can establish [Janoshik, snapshot 15 July 2026; Moore 2023, PMC10338602].
Regulatory purity requirements address another question. The EMA guideline specifies impurity reporting above 0.1%, identification above 0.5% and qualification above 1.0% for peptide-related impurities [EMA/CHMP/CVMP/QWP/367182/2025, section 4.4.1]. FDA guidance describes a 0.5% threshold for a new peptide-related impurity in its specified drug-substance context [FDA, archived 14 December 2025]. These thresholds do not turn a research-vial certificate into an approved medicine's label.
Our published record contains 80 reports across 32 products: 48 manufacturer reports, 29 community reports and 3 commissioned by us; Janoshik issued 52 [PeptidesDirect lab-report API, 12 September 2026]. Liquilabs reports LYO-0260 and LYO-0261, dated 29 June 2026, are examples from our commissioned panel with broader testing and identity assessed by separate parameters [Liquilabs commissioned reports]. A report concerns the sampled vial, batch and date. It does not clear every vial in a batch; the catalogue's batch-variation service addresses that separate question.
What have published analyses found in vials bought online?
Published market-surveillance measurements in the cited study concern semaglutide, not retatrutide [Ashraf 2024, PMID 39509151, Table 4]. The study analyzed 3 vials obtained during August to September 2023.
- Study finding
- 7.70%, 8.97%, 14.37%
- Comparator
- Claimed purity of at least 99%
- Study finding
- 28.56% to 38.69% above label
- Comparator
- Labeled content
The study also reported an elevated endotoxin content of 8.9511 EU/mg in one sampled vial, with the other two reported below the quantification limits of 2.8658 and 2.1645 EU/mg, a separate measurement from purity [Ashraf 2024, PMID 39509151, Table 4].
No published study reports laboratory analysis of consumer-purchased retatrutide vials in the documented searches. On 12 September 2026, PubMed's retatrutide AND (purity OR impurity OR counterfeit OR falsified OR "quality analysis") search returned 1 hit; ClinicalTrials.gov's retatrutide purity quality analysis vial search returned 0 studies. Branine's human case report describes an online-purchased retatrutide product but did not analyze its vial, so it supplies no measured composition or purity [Branine 2026, PMID 42669023].
Products mentioned
Retatrutide (LY3437943) is a synthetic 39-amino-acid peptide that acts on three receptors at once: GLP-1, GIP and glucagon. Supplied as a lyophilized powder for in-vitro research, with a batch-specific third-party certificate of analysis.
Sources
- Janoshik, 2026. Common GLP-1 peptide blind test (Semaglutide, Tirzepatide and Retatrutide). Snapshot 15 July 2026, published figures, subject to change. https://web.archive.org/web/20260715015040/https://janoshik.com/pricelist/common-glp-1-peptide-blind-test-semaglutide-tirzepatide-and-retatrutide/
- Moore, 2023. Pharmacopoeial methods overview, Table II. PMC10338602.
- EMA, 2025. Synthetic Peptides guideline, section 4.4.1. EMA/CHMP/CVMP/QWP/367182/2025.
- FDA. ANDAs for Certain Highly Purified Synthetic Peptide Drug Products. Archived 14 December 2025.
- Ashraf, 2024. Market-surveillance analysis, Table 4. J Med Internet Res. PMID 39509151; PMC11582493.
- Branine, 2026. Case report of an online-purchased retatrutide product. Cureus 18(8):e115260. PMID 42669023.
- PeptidesDirect, 2026. Published lab-report record, retrieved 12 September 2026. GET https://api.peptidesdirect.io/products/lab-reports.
- Liquilabs s.r.o., Czechia, 2026. Commissioned reports LYO-0259 to LYO-0261, dated 29 June 2026; worked examples LYO-0260 and LYO-0261. Verification: base.liquilabs.cz.
- PubMed and ClinicalTrials.gov, 2026. Retatrutide vial-analysis searches, documented 12 September 2026; search strings and counts reproduced above.
- PeptidesDirect, 2026. Internal Reddit question-corpus audit: 12-month corpus and 4 to 12 September 2026 window.
Research use only. Compounds sold here are supplied strictly for in-vitro research, not for human or veterinary use. Nothing on this page is a protocol, a recommendation or medical advice.
Research context for English-speaking buyers
Most of our English-speaking customers ship to the UK, Ireland, Malta or other English-as-second-language EU territories. The regulatory picture differs per country.
- Relevant authorities
- MHRA (UK, post-Brexit), HPRA (Ireland, EU-aligned), FDA Section 503A bulks list (US, restricted Cat 2 status of several peptides as of 2026)
- Customs and VAT
- EU shipments include VAT, the rate depends on the destination country; UK shipments after Brexit are now extra-EU and may attract UK VAT plus a handling fee at import
- Typical shipping window
- EU 2-4 working days, UK 4-7 working days, other international 7-14 working days, depending on customs
Research-grade peptides shipped from our EU warehouse are sold for laboratory use only and are not authorised for human or veterinary therapeutic application in any of the destination jurisdictions. US customers should be aware that the FDA Section 503A bulks list classification (and the April 2026 reclassification of twelve compounds) only governs compounding pharmacies, not direct-to-researcher imports for non-clinical work. UK buyers should declare the consignment on import and may be asked for a research justification by HMRC. We provide a CoA per batch identified by colour code rather than serial number; customs sometimes asks for this document when clearing the parcel.